APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trial

Ge Sun, John R. Davies, Tracey Mell, Mark Harland, Rasha M. H. Saleh, Amanda D. Race, Paul M. Loadman, Elizabeth A. Williams, Anne Marie Minihane, Mark A. Hull

Research output: Contribution to journalArticlepeer-review


Introduction: We examined the relationship between Apolipoprotein E (APOE) genotype and n-3 highly unsaturated fatty acid (HUFA) levels in participants of the seAFOod trial, who were undergoing colonoscopy surveillance after removal of colorectal polyps. Methods: Baseline and on-treatment (eicosapentaenoic acid [EPA] 2 g daily or placebo for 6 months) levels of n-3 HUFAs, and plasma 18-hydroxyeicosapentaenoic acid (HEPE), were analysed according to APOE genotype (based on polymorphisms rs429358 and rs7412) in 584 participants. Results: Before treatment, APOE2/2 individuals had lower levels, and APOE4/4 participants had higher levels, of n-3 HUFAs, including EPA, than APOE3/3 counterparts (P < 0.01 for the APOE2/2 versus APOE4/4 comparison). After EPA supplementation, n-3 HUFA levels were not significantly different when stratified by APOE genotype, although APOE4 carriers displayed lower plasma 18-HEPE levels than individuals without an APOE4 allele (P = 0.002). Conclusions: APOE genotype is associated with differential n-3 HUFA and 18-HEPE levels in individuals with multiple colorectal polyps.

Original languageEnglish
Article number102623
JournalProstaglandins, Leukotrienes and Essential Fatty Acids
Early online date31 May 2024
Publication statusPublished - 2024


  • Apolipoprotein E
  • Colorectal polyp
  • Highly unsaturated fatty acid
  • Oxylipin
  • single nucleotide polymorphism

Cite this